US › Healthcare

Akebia Ther (AKBA)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.32+0.76%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$53.5M
Revenue YoY
-6.6%
Net profit
$-9.1M
Profit YoY
-248.1%
EPS
$-0.03
EPS estimate
$-0.02
Net margin
-16.9%

EPS came in at -0.03 against a street estimate of -0.02 — a miss of 50.0%.

Key statistics

Market cap
$354.1M
Forward P/E
28.7
P/B
12.94
Book value
$0.10
EPS (TTM)
$-0.08
52-week high
$3.79
52-week low
$0.82
50-day MA
$1.15
200-day MA
$1.48
Beta
0.23

Analyst view

Analysts rate Akebia Ther a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $4.20.

Shareholding

Insiders
4.06%
Institutions
42.20%

Largest institutional holders

FundStake
BlackRock Inc6.97%
State Street Corp4.33%
Vanguard Capital Management, LLC4.16%
Geode Capital Management, LLC2.41%
The Goldman Sachs Group Inc1.34%
Citigroup Inc1.06%
Bank of America Corp1.03%
Qube Research & Technologies0.89%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Akebia Ther — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.